426 related articles for article (PubMed ID: 31262657)
1. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Li J; Qin S; Xu R; Yau TC; Ma B; Pan H; Xu J; Bai Y; Chi Y; Wang L; Yeh KH; Bi F; Cheng Y; Le AT; Lin JK; Liu T; Ma D; Kappeler C; Kalmus J; Kim TW;
Lancet Oncol; 2015 Jun; 16(6):619-29. PubMed ID: 25981818
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
10. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T
Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399
[TBL] [Abstract][Full Text] [Related]
11. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo C; Chénard-Poirier M; Roda D; de Miguel M; Harris SJ; Candilejo IM; Sriskandarajah P; Xu W; Scaranti M; Constantinidou A; King J; Parmar M; Turner AJ; Carreira S; Riisnaes R; Finneran L; Hall E; Ishikawa Y; Nakai K; Tunariu N; Basu B; Kaiser M; Lopez JS; Minchom A; de Bono JS; Banerji U
Lancet Oncol; 2020 Nov; 21(11):1478-1488. PubMed ID: 33128873
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
Suzuki T; Sukawa Y; Imamura CK; Masuishi T; Satake H; Kumekawa Y; Funakoshi S; Kotaka M; Horie Y; Kawai S; Okuda H; Terazawa T; Kondoh C; Kato K; Yoshimura K; Ishikawa H; Hamamoto Y; Boku N; Takaishi H; Kanai T
Clin Colorectal Cancer; 2020 Mar; 19(1):13-21.e3. PubMed ID: 31732439
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
Clarke JM; Blobe GC; Strickler JH; Uronis HE; Zafar SY; Morse M; Dropkin E; Howard L; O'Neill M; Rushing CN; Niedzwiecki D; Watson H; Bolch E; Arrowood C; Liu Y; Nixon AB; Hurwitz HI
Cancer Chemother Pharmacol; 2019 Oct; 84(4):909-917. PubMed ID: 31444620
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).
Ishiyama S; Yamada T; Nakamura M; Enomoto M; Sugimoto K; Yokomizo H; Kosugi C; Ohta R; Ishimaru K; Sonoda H; Ishibashi K; Kuramochi H; Yoshida Y; Ichikawa D; Hirata K; Yoshida H; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
Int J Clin Oncol; 2022 Aug; 27(8):1300-1308. PubMed ID: 35635652
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Strumberg D; Scheulen ME; Schultheis B; Richly H; Frost A; Büchert M; Christensen O; Jeffers M; Heinig R; Boix O; Mross K
Br J Cancer; 2012 May; 106(11):1722-7. PubMed ID: 22568966
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
Xu J; Xu RH; Qin S; Pan H; Bai Y; Chi Y; Wang L; Bi F; Cheng Y; Liu T; Ma D; Shen L; Ba Y; Liang J; Wang X; Yau TCC; Ma BB; Yeh KH; Lin JK; Kappeler C; Shapiro J; Kalmus J; Li J
J Gastroenterol Hepatol; 2020 Aug; 35(8):1307-1316. PubMed ID: 31900959
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
